QuickView for MYC;jsessionid=D40631F1092410AB2ABA503D9BDA95CF;jsessionid=24481B37E3EE0660CC48D46677C179DD;jsessionid=1533985870406616C8C2331B79422650;jsessionid=1AC92DFE91BCB6B68A66ED6CD11BEA33;jsessionid=4DF43BF7604689C87D84075E4CE06FBA (gene)

1. Survey of activation-induced genome architecture reveals a novel enhancer of Myc.
2. Nuclear to cytoplasmic transport is a druggable dependency in MYC-driven hepatocellular carcinoma.
3. Rewired Metabolism Caused by the Oncogenic Deregulation of MYC as an Attractive Therapeutic Target i…
4. MYC overexpression leads to increased chromatin interactions at super-enhancers and MYC binding site…
5. Therapeutic targeting of "undruggable" MYC.

There were no clinical trials for MYC;jsessionid=D40631F1092410AB2ABA503D9BDA95CF;jsessionid=24481B37E3EE0660CC48D46677C179DD;jsessionid=1533985870406616C8C2331B79422650;jsessionid=1AC92DFE91BCB6B68A66ED6CD11BEA33;jsessionid=4DF43BF7604689C87D84075E4CE06FBA